AstraZeneca (AZN) Reports Statistically Significant Data from OSKIRA-1
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
